Scholars@Duke
Suzanne E Wardell

Suzanne E Wardell

Assistant Research Professor of Pharmacology and Cancer Biology
Pharmacology & Cancer Biology
suzanne.wardell@duke.edu
Box 103057, Durham, NC 27710
MSRB3 2130, Box 103057, Durham, NC 27710

Scholarly Works - Conferences

Combination mTORC1/2 and BCL- XL inhibition in endocrine and CDK4/6-resistant estrogen receptor-positive breast cancer.

Conference Journal of Clinical Oncology · May 20, 2019 e14653 Background: Endocrine therapy plus CDK 4/6 inhibition has led to impressive improvements in progression-free survival in patients with advanced, estrogen receptor positive (ER+)/HER2-negative (HER2-) breast cancer. Resista ... Full text Cite

Abstract 1805: Development of a selective androgen receptor degrader (SARD) for treatment of castration-resistant prostate cancer

Conference Cancer Research · July 1, 2018 AbstractCurrent treatments for prostate cancer are centered on blocking androgen-signaling axis, which is the target of several clinical androgen receptor (AR) antagonists such as enzalutamide. Recent studie ... Full text Cite

Abstract 5496: A predictive model for selective targeting of the Warburg effect through GAPDH inhibition with a natural product

Conference Cancer Research · July 1, 2018 AbstractCancer cells undergo numerous adaptive processes to sustain growth and survival. One notable mechanism is by rewiring metabolism, most prominently through a phenomenon known as the Warburg effect (WE ... Full text Cite

Discovery of a selective androgen receptor degrader (SARD) for treatment of castration-resistant prostate cancer

Conference ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY · August 20, 2017 Link to item Cite

SERMs and SERDs as the cornerstone of endocrine therapy in ER alpha-positive breast cancer

Conference ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY · August 20, 2016 Link to item Cite

Targeting protein-protein interactions for disruption of KDM1A (LSD1) complexes

Conference ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY · March 13, 2016 Link to item Cite

Abstract P3-14-04: Effects of the dual selective CYP17 lyase inhibitor and androgen receptor (AR) antagonist, VT-464, on AR+ and ER+ tumor models in vitro and in vivo

Conference Cancer Research · February 15, 2016 AbstractVT-464 is a lyase-selective inhibitor of the dual-activity CYP17A1 enzyme that is required for the synthesis of androgens and estrogens in the gonads, adrenals, and tumors. In addition to its role as ... Full text Cite

Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model.

Conference Journal of Clinical Oncology · March 1, 2015 263 Background: MDV3100 inhibits binding of androgens to AR and abiraterone is known to block androgen production through CYP17 inhibition; both are effective treatments for castration-resistant prostate cancer (CRPC, yet cross-r ... Full text Cite

Progesterone receptor interacting coregulatory proteins and cross talk with cell signaling pathways.

Conference J Steroid Biochem Mol Biol · December 2002 Progesterone receptor (PR) is a member of the nuclear receptor family of ligand-dependent transcription activators and is expressed as two different sized proteins from a single gene; PR-A and PR-B. The two PR isoforms are identical in their DNA binding do ... Full text Link to item Cite